Analyze the effect of proton pump inhibitors combined with gastrointestinal motility drugs on salivary pepsin in patients with gastroesophageal reflux disease (GERD).

93 patients with GERD who were admitted to the People's Hospital of Xinjiang Uygur Autonomous Region from January 2020 to May 2021 were selected as the research objects, and were randomly divided into the study group and the control group using the digital table method. Among them, 47 cases in the experimental group were treated with proton pump inhibitors combined with gastrointestinal motility drugs; 46 cases in the control group were treated with proton pump inhibitors alone. The scores of GerdQ, RDQ, RSI, RSF scale before and after treatment were recorded for the two groups of patients, as well as the pepsin test values of saliva samples from fasting in the morning, 2 h after lunch, and symptoms.

Before treatment, there was no significant difference in general data such as gender (male/female), age, BMI, smoking, drinking, DeMeester score, etc between the two groups of patients (all P＞0.05). Compared with the control group, the GerdQ, RDQ, RSI, RSF and other scores of the study group decreased more significantly after treatment, and the differences between the two groups were statistically significant (P＜0.05). Compared with the control group, the salivary pepsin concentration of the study group dropped more significantly in the morning on an empty stomach, 2 hours after lunch, and symptoms, and the difference between the two groups was statistically significant (statistics: experimental group n=47; control Group n=46; statistical values t=12.957, 14.573, 5.446, -17.219, -5.156; P＜0.05).

Proton pump inhibitors combined with gastrointestinal motility drugs can more significantly reduce the salivary pepsin concentration of patients with GERD, and at the same time more significantly alleviate the symptoms of GERD and reduce the reflux score, which has a more significant effect on disease control.